The flow cytometry analysis showed that, compared with the saline-treated control group (Group A), percentage of CD45+/PD-L1+ cells and CD11b+/PD-L1+ cells on day 4 were significantly increased in MC38 tumor-bearing mice treated using 177Lu TRT (Group B), whereas no significant difference was observed in the level of CD45-/PD-L1 and CD4+/ Foxp3+ cells between the control and therapeutic groups (Group B-D) (Figure 6A). This evidence concerns the gene PTPRC and neoplasm.